Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer
A combination of vemurafenib, cetuximab combined with camrelizumab exhibited manageable adverse reactions and efficacy in BRAF V600E-mutated/MSS patients with metastatic colorectal cancer who progressed after standard treatment. This is a pilot study and a larger phase II trials is planned to validate the findings. (ClinicalTrials.gov ID: NCT05019534).
Authors
- Gui-Xia Wei
- Jie Tang (ORCID: https://orcid.org/0000-0001-8841-0781)
- Meng Qiu (ORCID: https://orcid.org/0000-0003-3722-6938)
- Peng Cao (ORCID: https://orcid.org/0000-0002-6105-8543)
- Li Wang (ORCID: https://orcid.org/0000-0003-1585-8846)
- Weibing Leng (ORCID: https://orcid.org/0000-0002-9218-3988)
- Yuwen Zhou
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1186/s12967-025-07312-6
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Department of Science and Technology of Sichuan Province
- European Society for Medical Oncology
- National Health Commission of the People's Republic of China